Form 4: Kewaunee Scientific Corp Executive Sells Shares

Sentiment:

SEC Form 4 Filing


Ryan S. Noble, VP of Sales & Marketing-Americas at Kewaunee Scientific Corp, sold 1,500 shares of common stock on December 30, 2024.

Summary

  • Ryan S. Noble, a VP at Kewaunee Scientific Corp, sold 1,500 shares of the company's common stock on December 30, 2024.
  • The sale was executed at a price of $66 per share.
  • Following the transaction, Mr. Noble directly owns 11,823 shares of Kewaunee Scientific Corp.

Sentiment

Score: 5

Explanation: The document is a neutral disclosure of an insider stock sale. It doesn't inherently indicate positive or negative sentiment about the company's performance.

Industry Context

This is a routine disclosure of an insider transaction and is typical for publicly traded companies. It does not indicate any specific trend in the industry.

Comparison to Industry Standards

  • Insider trading disclosures are a standard practice for all publicly listed companies.
  • The sale of shares by an executive is a common occurrence and does not necessarily indicate a negative outlook for the company.
  • Similar filings are made by executives at companies like Thermo Fisher Scientific, Agilent Technologies, and Waters Corporation, which are also in the scientific equipment and laboratory solutions sector.

Stakeholder Impact

  • The sale of shares by an executive may have a minor impact on shareholder sentiment, but it is a common occurrence.

Key Dates

DateDescription
12/30/2024Date of the stock sale transaction.
01/06/2025Date the form was signed by the attorney-in-fact.

Keywords

Kewaunee Scientific Corp, insider trading, stock sale, Ryan S. Noble, executive transaction, KEQU

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.